{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:51:15Z","timestamp":1791503475390,"version":"4.3.4"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802540"],"award-info":[{"award-number":["81802540"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173372"],"award-info":[{"award-number":["82173372"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004767","name":"University of Science and Technology Liaoning","doi-asserted-by":"publisher","award":["2021JH1\/10400045"],"award-info":[{"award-number":["2021JH1\/10400045"]}],"id":[{"id":"10.13039\/501100004767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018934","name":"Liaoning Provincial Department of Human Resources and Social Security","doi-asserted-by":"publisher","award":["LJKMZ20221138"],"award-info":[{"award-number":["LJKMZ20221138"]}],"id":[{"id":"10.13039\/100018934","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019033","name":"Key Research and Development Program of Liaoning Province","doi-asserted-by":"publisher","award":["2025JH2\/101800396"],"award-info":[{"award-number":["2025JH2\/101800396"]}],"id":[{"id":"10.13039\/501100019033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105637","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:42:40Z","timestamp":1791319360000},"page":"105637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The impact of the tumor microenvironment on immune checkpoint inhibitor resistance in prostate cancer: Mechanistic insights and therapeutic strategies"],"prefix":"10.1016","volume":"228","author":[{"given":"Siyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2026.105637_bib1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1470-2045(25)00209-8","article-title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","volume":"26","author":"Agarwal","year":"2025","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105637_bib2","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105637_bib3","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105637_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105637_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105637_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109844","article-title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy","volume":"37","author":"Binnewies","year":"2021","journal-title":"Cell. Rep."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105637_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158340","article-title":"Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer","volume":"22","author":"Brandum","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105637_bib8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.ccell.2024.06.003","article-title":"Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution","volume":"42","author":"Casanova-Salas","year":"2024","journal-title":"Cancer Cell."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105637_bib9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/cac2.12596","article-title":"Dysfunction of dendritic cells in tumor microenvironment and immunotherapy","volume":"44","author":"Chen","year":"2024","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12943-024-02137-1","article-title":"Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota","volume":"23","author":"Chen","year":"2024","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105637_bib11","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.1097\/JS9.0000000000002895","article-title":"Regulation of macrophage plasticity by circCCDC7 19-13 through HSP90 inhibition suppresses prostate cancer progression and metastasis: a translational study","volume":"111","author":"Cheng","year":"2025","journal-title":"Int. J. Surg."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105637_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133473","article-title":"Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?","volume":"15","author":"Chetta","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105637_bib13","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.4049\/jimmunol.1500959","article-title":"Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity","volume":"195","author":"Cimen Bozkus","year":"2015","journal-title":"J. Immunol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105637_bib14","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/s41388-019-0688-7","article-title":"Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8\/miR21 axis","volume":"38","author":"Comito","year":"2019","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105637_bib15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1158\/2326-6066.CIR-19-0371","article-title":"Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell-Mediated Immune Suppression and Tumor Progression","volume":"8","author":"Consiglio","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105637_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100305","article-title":"Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions","volume":"9","author":"Crocetto","year":"2025","journal-title":"J. Liq. Biopsy"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105637_bib17","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105637_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/iju.15378","article-title":"Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer","volume":"31","author":"De Velasco","year":"2024","journal-title":"Int. J. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105637_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105637_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2026-014803","article-title":"Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial","volume":"14","author":"Eefsen","year":"2026","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12392","article-title":"Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives","volume":"43","author":"Fang","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.critrevonc.2026.105637_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2021.09.043","article-title":"Nivolumab plus docetaxel in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial","volume":"160","author":"Fizazi","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105637_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004761","article-title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","volume":"10","author":"Fizazi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1470-2045(25)00566-2","article-title":"Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial","volume":"27","author":"Fizazi","year":"2026","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105637_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI171154","article-title":"PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice","volume":"134","author":"Frijlink","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105637_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105637_bib27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","article-title":"Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy","volume":"42","author":"Geels","year":"2024","journal-title":"Cancer Cell."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105637_bib28","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105637_bib29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.4049\/jimmunol.174.4.1783","article-title":"Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism","volume":"174","author":"Gondek","year":"2005","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105637_bib30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.annonc.2025.05.007","article-title":"Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study","volume":"36","author":"Graff","year":"2025","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105637_bib31","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.annonc.2025.05.008","article-title":"Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study","volume":"36","author":"Gratzke","year":"2025","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105637_bib32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105637_bib33","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105637_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","article-title":"Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses","volume":"14","author":"Hirz","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105637_bib36","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","article-title":"Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies","volume":"3","author":"Hossain","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105637_bib37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","article-title":"Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer","volume":"40","author":"Huang","year":"2022","journal-title":"Cancer Cell."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105637_bib38","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00262-014-1591-2","article-title":"Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer","volume":"63","author":"Idorn","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105637_bib39","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105637_bib40","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","article-title":"Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy","volume":"179","author":"Jiao","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105637_bib42","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105637_bib44","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105637_bib45","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221757","article-title":"IL-6 selectively suppresses cDC1 specification via C\/EBP\u03b2","volume":"220","author":"Kim","year":"2023","journal-title":"J. Exp. Med."},{"issue":"7051","key":"10.1016\/j.critrevonc.2026.105637_bib46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature03847","article-title":"Licensing of natural killer cells by host major histocompatibility complex class I molecules","volume":"436","author":"Kim","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105637_bib47","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.juro.2007.03.109","article-title":"Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition","volume":"178","author":"Kitamura","year":"2007","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105637_bib48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105637_bib49","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1_ement","key":"10.1016\/j.critrevonc.2026.105637_bib50","article-title":"PD-1 expression on Foxp3+ Treg cells modulates CD8+ T cell function in prostatic tumor microenvironment","volume":"198","author":"Kumar","year":"2017","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105637_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105637_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.566511","article-title":"Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers","volume":"10","author":"Larionova","year":"2020","journal-title":"Front. Oncol."},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105637_bib53","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1200\/JCO-24-02637","article-title":"Nivolumab and ipilimumab for metastatic castration-resistant prostate cancer with an immunogenic signature: the multicenter, two-cohort, phase II NEPTUNES study","volume":"43","author":"Leone","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105637_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105283","article-title":"From cold to hot: A 'Prime, Activate, Sustain' framework for precision remodeling of the tumor microenvironment in prostate cancer","volume":"222","author":"Li","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib55","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1038\/s41467-022-34871-9","article-title":"ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib56","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1038\/s41467-025-61560-0","article-title":"YY1 enhances HIF-1\u03b1 stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105637_bib57","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase Ia\/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors","volume":"28","author":"Lim","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"599","key":"10.1016\/j.critrevonc.2026.105637_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"32","key":"10.1016\/j.critrevonc.2026.105637_bib59","article-title":"Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer","volume":"102","author":"Liu","year":"2023","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.critrevonc.2026.105637_bib60","article-title":"Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors","volume":"16","author":"Lu","year":"2025","journal-title":"Front. Immunol."},{"issue":"7647","key":"10.1016\/j.critrevonc.2026.105637_bib61","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"issue":"8048","key":"10.1016\/j.critrevonc.2026.105637_bib62","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105637_bib63","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.7150\/thno.73152","article-title":"Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105637_bib64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105637_bib65","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1541-7786.MCR-24-0791","article-title":"Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis","volume":"23","author":"Mei","year":"2025","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105637_bib66","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"issue":"69","key":"10.1016\/j.critrevonc.2026.105637_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi4613","article-title":"Transforming growth factor-\u03b21 in regulatory T cell biology","volume":"7","author":"Moreau","year":"2022","journal-title":"Sci. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105637_bib68","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s43018-021-00185-w","article-title":"EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer","volume":"2","author":"Morel","year":"2021","journal-title":"Nat. Cancer"},{"issue":"Pt 3","key":"10.1016\/j.critrevonc.2026.105637_bib69","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semcancer.2022.02.017","article-title":"Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis","volume":"86","author":"Mughees","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105637_bib70","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-24-0400","article-title":"Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105637_bib71","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","article-title":"T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer","volume":"26","author":"Obradovic","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105637_bib72","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3389\/fimmu.2018.02358","article-title":"Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration","volume":"9","author":"Parodi","year":"2018","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105637_bib73","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1158\/0008-5472.CAN-15-1965","article-title":"Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity","volume":"76","author":"Pasero","year":"2016","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105637_bib74","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-16-0778","article-title":"Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity","volume":"7","author":"Patnaik","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib75","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2562220","article-title":"Characterization of the immune landscape in healthy mouse prostate and during prostate cancer progression","volume":"14","author":"Pervizou","year":"2025","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105637_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188356","article-title":"Fibrosis and cancer: A strained relationship","volume":"1873","author":"Piersma","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105637_bib77","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105637_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005060","article-title":"Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors","volume":"10","author":"Potluri","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib79","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat. Med."},{"issue":"6-7","key":"10.1016\/j.critrevonc.2026.105637_bib80","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3109\/08820139.2012.680634","article-title":"Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives","volume":"41","author":"Raber","year":"2012","journal-title":"Immunol. Invest."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054251","article-title":"The role of hypoxia-inducible factor 1\u03b1 in determining the properties of castrate-resistant prostate cancers","volume":"8","author":"Ranasinghe","year":"2013","journal-title":"PLoS. One"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105637_bib82","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/2326-6066.CIR-14-0079","article-title":"Cross-presentation of the oncofetal tumor antigen 5T4 from irradiated prostate cancer cells: a key role for heat-shock protein 70 and receptor CD91","volume":"3","author":"Salimu","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105637_bib83","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105637_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.755433","article-title":"Immunogenic cell death and immunomodulatory effects of cabozantinib","volume":"11","author":"Scirocchi","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-72242-w","article-title":"Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial","volume":"17","author":"Sharma","year":"2026","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105637_bib86","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib87","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105637_bib88","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105637_bib89","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/0008-5472.CAN-24-0932","article-title":"YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer","volume":"84","author":"Song","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib90","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.CAN-09-2587","article-title":"Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine","volume":"70","author":"Srivastava","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105637_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216034","article-title":"PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration","volume":"555","author":"Su","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib92","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105637_bib93","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105637_bib94","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105637_bib95","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0228","article-title":"The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications","volume":"12","author":"Torabinejad","year":"2023","journal-title":"Eur. Thyroid. J."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105637_bib96","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105637_bib97","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.euo.2025.04.016","article-title":"Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer","volume":"8","author":"van Wilpe","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105637_bib98","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pros.23929","article-title":"Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment","volume":"80","author":"Vickman","year":"2020","journal-title":"Prostate"},{"issue":"415","key":"10.1016\/j.critrevonc.2026.105637_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2026.105637_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216300","article-title":"TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer","volume":"568","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib101","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1038\/s41467-025-62381-x","article-title":"AR(+)TREM2(+) macrophage induced pathogenic immunosuppression promotes prostate cancer progression","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105637_bib102","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.eururo.2022.01.028","article-title":"Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105637_bib104","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3389\/fimmu.2019.01399","article-title":"Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor","volume":"10","author":"Yan","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105637_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108278","article-title":"PPAR\u03b1 Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction","volume":"33","author":"Yin","year":"2020","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105637_bib106","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5808962","article-title":"Prostaglandin E(2) Inhibits Prostate Cancer Progression by Countervailing Tumor Microenvironment-Induced Impairment of Dendritic Cell Migration through LXR\u03b1\/CCR7 Pathway","volume":"2018","author":"Youlin","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105637_bib107","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","article-title":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b\/2 KEYNOTE-365 Cohort B Study","volume":"82","author":"Yu","year":"2022","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105637_bib108","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.apsb.2021.07.016","article-title":"Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8(+) T cell-mediated ferroptosis in castration-resistant prostate cancer","volume":"12","author":"Zhou","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"81","key":"10.1016\/j.critrevonc.2026.105637_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade4656","article-title":"Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer","volume":"8","author":"Zhu","year":"2023","journal-title":"Sci. Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600524X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600524X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:18:42Z","timestamp":1791501522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600524X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":109,"alternative-id":["S104084282600524X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105637","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the tumor microenvironment on immune checkpoint inhibitor resistance in prostate cancer: Mechanistic insights and therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105637"}}